Clin Pediatr Hematol Oncol.
2009 Oct;16(2):130-138.
The Enhancing Effect of Human Parathyroid Hormone on the Hematopoietic Recovery in the Mice Model with Chronic Bone Marrow Hypoplasia
- Affiliations
-
- 1Department of Pediatrics, College of Medicine, Hanyang University, Seoul, Korea. cord@hanyang.ac.kr
- 2Department of Pathology, College of Medicine, Hanyang University, Seoul, Korea.
- 3Department of Pharmacology, College of Medicine, Hanyang University, Seoul, Korea.
Abstract
- PURPOSE
Osteoblasts have been found to be important components of the niche, and produce hematopoietic growth factors and are activated by parathyroid hormone (PTH) or PTH-related protein. We performed the pilot study to reveal the effect of human PTH (hPTH) on the hematopoietic recovery in the mice with chronic bone marrow hypoplasia (CBMH) model. METHODS: We performed this study by using 10 female BALB/c mice. At first we demonstrated the CBMH model (n=6) in the mice with 10 doses of busulfan (9 mg/kg/day). Thereafter, we injected daily hPTH (40microgram/kg/day) (n=2, PTH group) or vehicle (n=2, control group) intraperitoneally in the CBMH mice alternating weekly for 7 weeks. We compared the CBC profiles as well as microarchitecture and hematopoietic cellularity between 2 groups. RESULTS: In the CBMH model, the hematopoietic cellularity and trabecular bone architecture were markedly decreased compared to the control group. However, the hematopoietic cellularity and trabecular tunnelling were increased in bone marrow of hPTH-treated mice compared with control (CBMH) mice. When the CBC profiles were checked in each 1 mouse of both group, trilineage components of CBC showed more increment in hPTH-treated mouse than control mouse. CONCLUSION: We have demonstrated a model of chronic bone marrow hypoplasia, and also the potential effect of hPTH for enhancing the hematopoietic function as well as the trabecular bone formation. Further experiments would be required to explore that hPTH could be used as a potential agent promoting expansion of hematopoietic cells in patients with aplastic anemia as well as stem cell transplantation setting.